Status:
TERMINATED
AZD7325 Japan Multiple Ascending Dose (MAD) Study
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Eligibility:
MALE
20-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety and tolerability after repeated ascending doses of AZD7325 in Japanese healthy male subjects.
Eligibility Criteria
Inclusion
- Japanese subjects
Exclusion
- Significant illness, as judged by the investigator, within 2 weeks of Day 1
- Enrollment in another concurrent investigational study or intake of an investigational drug within 4 months prior to the screening visit
- Blood loss in excess of 200 mL within 30 days of Day 1, in excess of 400 mL within 90 days of Day 1, or in excess of 1200 mL within 1 year of Day 1
- Clinically relevant abnormalities in physical examinations, vital signs, clinical chemistry, hematology or urinalysis as judged by the investigator and/or sponsor
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2009
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00945425
Start Date
July 1 2009
End Date
November 1 2009
Last Update
February 16 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.